Bayer’s 55% Surge Faces a Test: Legal Relief Meets Overbought Reality
Published on 07/03/2026 at 09:43 | Redaktion boerse-global.de
The euphoria surrounding Bayer’s landmark Supreme Court victory has propelled its shares to within striking distance of a 52-week high, but the stock’s technical condition and an unresolved settlement hearing threaten to cap further gains. The DAX-listed group now trades at €53.48 after a 55% climb over the past 30 days, and is up almost 40% since the start of the year. Yet the Relative Strength Index has soared to 85.5 – deep in overbought territory – while the share sits nearly 38% above its 50-day moving average of €38.87, a gap that historically invites profit-taking.
The rally’s catalyst was a seismic legal shift. On June 25, 2026, the US Supreme Court ruled 7-2 that federal law preempts state-level lawsuits over missing cancer warnings on glyphosate packaging. The decision effectively removes the legal foundation for thousands of pending cases against Bayer, which inherited the litigation through its $63 billion acquisition of Monsanto. Investors interpreted the verdict as a turning point after years of legal setbacks, triggering a wave of buying that briefly pushed the stock to a 52-week peak of €53.58.
Bayer wasted no time capitalising on the ruling. On July 1, it launched a new US subsidiary called Ruveon LLC, based in St. Louis and led by Alfonso Alba Ordóñez. The entity consolidates the company’s entire American glyphosate business, handling pricing, distribution and production autonomously while remaining a wholly owned unit of the parent. The goal is twofold: to isolate future legal exposure and to sharpen operational focus in an increasingly competitive market. Bayer also filed an antidumping petition with US authorities, alleging that Chinese glyphosate imports are being sold at margins of 69% to 446%, and is seeking tariffs to protect its domestic capacity – which accounts for roughly 60% of the US total.
Should investors sell immediately? Or is it worth buying Bayer?
The restructuring comes with ambitious cost targets. Ruveon is expected to reduce operating expenses by 5% to 8% over three years, even as the geographic mix shifts. The US glyphosate market is projected to shrink by about 4% annually, while Latin America is forecast to expand at a 6% to 8% clip. Deutsche Bank Research responded by raising its price target to €60 and reiterating a “Buy” rating, arguing that the glyphosate overhang is fading. Over the past twelve months, Bayer shares have more than doubled – a 105% gain that suggests a structural turnaround.
Not everyone is convinced the rally can hold. The provisional $7.25 billion settlement that Bayer reached to resolve outstanding claims has yet to receive final approval. A critical court hearing is scheduled for August 19, and any delays or objections could puncture the current sense of relief. Some discounted cash-flow models point to valuations that are more than 50% above fair value, and farm groups have already voiced opposition to the proposed antidumping tariffs, arguing they would raise input costs. If Ruveon’s earnings are squeezed before the cost savings materialise, the stock’s elevated multiples could quickly deflate.
From a chart perspective, the next few weeks are likely to be defined by the tension between legal optimism and technical consolidation. As long as Bayer holds above the €50 mark and the Ruveon demerger proceeds smoothly, the analyst target of €60 remains within reach. A break below the 50-day moving average, however, would invalidate the bull case and signal that the post-ruling euphoria has run its course. The annualised volatility of 63.19% underscores the nervous backdrop. All eyes now turn to the August 19 hearing – the moment the market will learn whether Bayer’s new legal shield is truly watertight, or just another question mark dressed as a solution.
Ad
Bayer Stock: New Analysis - 3 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
